Associate Professor, Medicine, Tufts Medical Center
Oncology
Dr. Tarun Kewalramani, MD
|
|
Give Review
Tarun Kewalramani is an expert in the field of Oncology. He researched medicine at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19/29 in Research/PrimaryCare. Tarun Kewalramani is also a published doctor. He has 28 publication published. The most recent publication is: Effect of single-base substitutions in the central domain of virus-associated RNA I on its function. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.
- Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?
- High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
- Effect of single-base substitutions in the central domain of virus-associated RNA I on its function.
- Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin''s lymphoma.
- Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
- Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin''s disease or aggressive non-Hodgkin''s...
- Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
- High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
- Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.
- Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.
- The serum IL-12:IL-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation.
- Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
- High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
- Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
- Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
- American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
- A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
- Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
- Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
- Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with re...
- Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and ...
- Palifermin for oral mucositis after intensive therapy for hematologic cancers.
- Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin''s disease.
- Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
- Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell...
Schools
Northwestern University Feinberg School Of Medicine
Boston Medical Center
Memorial SloanKettering Cancer Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Doctors Specialties
- Oncology
Accepted Insurances
Education
-
Memorial Sloan-Kettering Cancer Center -
Boston University Medical Center -
Northwestern University Feinberg School of Medicine
Hospital
-
Lahey Hospital & Medical Center, Burlington
Drug Facts
| NPI NUMBER | 1538130570 | |
| NPPES Provider LastName | KEWALRAMANI | |
| NPPES Provider FirstName | TARUN | |
| NPPES Provider ZIPCode | 018050001 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 237.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538130570 |
| Last Name Of The Provider | KEWALRAMANI |
| First Name Of The Provider | TARUN |
| View All |
Similar Doctors
|
Dr. John H. Wolff, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Paul Hesketh, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joyce A. McCaffrey, MD |
|
|
Dr. Todd Shuster, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Corrine Zarwan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Neela Natarajan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Oberfield, MD
This Doctor is OpenDoctor Recommended.
|